TherapeuticsMD, Inc. — fact timeline

TherapeuticsMD, Inc. reported the full year ended December 31, 2025 results: revenue $3.0 million, net income $(0.7) million, EPS $(0.06) per basic and diluted common share.

“or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations ● License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended December 31, 2025, an increase of $1.3 million, or 71.6%, compared to $1.8 million in license revenue during the year ended December 31, 2024. The increase”

TherapeuticsMD, Inc. engaged Carr, Riggs & Ingram, L.L.C. as its auditor.

“On January 15, 2026, the Audit Committee of the Board of Directors of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), approved the appointment of Carr, Riggs & Ingram, L.L.C. (“CRI”) as the Company’s independent registered public accounting firm, effective immediately.”

TherapeuticsMD, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.3 million, net income $(0.8) million, EPS $(0.07) per basic and diluted common share.

“in revenue, net and other income based on the proportion of the sales from each of our licensed products. Based on sales of our licensed products, the Company recognized $0.3 million in revenue, net, and approximately $0.3 million in other income in the three months ended March 31, 2024 related to net license royalties. Total Operating Expenses from”

TherapeuticsMD, Inc. reported the full year ended December 31, 2023 results: net income Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, EPS $(0.74) per basic and diluted common share.

“TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.”

TherapeuticsMD, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss from continuing operations was $1.4 million for the quarter ended September 30, 2023, or $0.13 per basic and di, EPS $0.13 per basic and diluted common share.

“TherapeuticsMD Announces Third Quarter 2023 Financial Results”

Joseph Ziegler was appointed as Principal Financial and Accounting Officer at TherapeuticsMD, Inc..

“Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the effective date of Mr. Donegan’s resignation.”

Michael C. Donegan resigned as Principal Financial and Accounting Officer at TherapeuticsMD, Inc..

“On August 17, 2023, Mr. Michael C. Donegan, the Principal Financial and Accounting Officer of the Company, notified the Company of his decision to resign from such positions, effective as of August 17, 2023.”

TherapeuticsMD, Inc. reported second quarter ended June 30, 2023 results: revenue $0.4 million, net income $2.4 million, EPS $(0.24) per basic and diluted common share.

“License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended June 30, 2023”

TherapeuticsMD, Inc. engaged Berkowitz Pollack Brant as its auditor.

“engaged Berkowitz Pollack Brant ("BPB") as the Company’s independent registered public accounting firm for the 2023 fiscal year”

TherapeuticsMD, Inc. dismissed Grant Thornton LLP as its auditor.

“dismissed Grant Thornton LLP ("GT") as the Company’s independent registered public accounting firm”

TherapeuticsMD, Inc.: An amendment to the bylaws was adopted to opt out of Nevada's control share acquisition statutes with respect to the Subscription Agreement and related transactions (effective 2023-06-29).

“Amendment to the Bylaws Effective June 29, 2023, the Board of Directors of the Company adopted and approved an amendment to the Bylaws of the Company, as previously amended (the “Bylaw Amendment”), to render the provisions of Nevada’s acquisition of controlling interest statutes (NRS 78.378 through 78.3793, inclusive) not applicable to the Subscription Agreement, the acquisition of any shares of the Company’s capital stock thereunder or the consummation of any transactions contemplated thereby, or by the other documents, instruments and arrangements contemplated by the Subscription Agreement.”

TherapeuticsMD, Inc. shareholders approved Ratification of appointment of Grant Thornton LLP as independent auditor for fiscal year 2023 at the 2023-06-26 meeting.

“The Company’s stockholders ratified the appointment of Grant Thornton, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2023, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 5,875,689 162,089 13,371 0”

TherapeuticsMD, Inc. shareholders approved Approval of issuance of up to 5,000,000 shares of Common Stock in private placements to Rubric Capital Management LP under Nasdaq Rules 5635(b) and 5635(d) at the 2023-06-26 meeting.

“The Company’s stockholders approved the Private Placement Proposal, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 4,178,998 238,644 5,717 1,627,790”

TherapeuticsMD, Inc. shareholders approved Approval of amendment to Amended and Restated Articles of Incorporation to increase authorized shares of Common Stock from 12,000,000 to 32,000,000 at the 2023-06-26 meeting.

“The Company’s stockholders approved the Charter Amendment, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 5,431,781 595,133 24,235 0”

TherapeuticsMD, Inc. shareholders approved Non-binding advisory vote on named executive officer compensation for fiscal year 2022 at the 2023-06-26 meeting.

“The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2022, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 4,007,930 317,286 98,143 1,627,790”

TherapeuticsMD, Inc. shareholders approved Election of four directors at the 2023-06-26 meeting.

“All of the four nominees for the Company’s Board of Directors were elected to serve until the Company’s next annual meeting of stockholders or until their successors are duly elected and qualified, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Tommy G. Thompson 4,124,794 298,565 1,627,790 Cooper C. Collins 4,149,214 274,145 1,627,790 Gail K. Naughton, Ph.D. 4,153,469 269,890 1,627,790 Justin Roberts 4,085,664 337,695 1,627,790”

TherapeuticsMD, Inc. reported first quarter ended March 31, 2023 results: revenue $0.4 million, net income $2.3 million, EPS $0.24 per basic and diluted common share.

“Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022. License and Service Revenues from Continuing Operations • License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 2023, compared to $0.7 million in license and service revenue related to sales to other licensees for the first quarter of 2022.”

TherapeuticsMD, Inc. entered into Subscription Agreement with Rubric Capital Management LP valued at $5,000,000 (effective 2023-05-01).

“On May 1, 2023, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company agreed to sell to the Investor, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), from time to time during the term of the Subscription Agreement, at a purchase price of the five-day volume-weighted average price of the Company’s common stock at the time of the sale of such Shares, at an aggregate purchase price of up to $5,000,000 (collectively, the “Private Placement”).”

TherapeuticsMD, Inc. reported the full year ended December 31, 2022 results: revenue $70.0 million, net income $1.1 million, EPS $0.12 per basic share.

“License Revenues from Continuing Operations • License revenues from continuing operations, which are revenues from continuing operations related to license agreements, were $70.0 million for the year ended December 31, 2022, compared to $2.6 million for 2021. The increase in license revenues was a result of the allocation of the initial upfront payment and”

Michael Donegan was appointed as Principal Financial Officer and Principal Accounting Officer at TherapeuticsMD, Inc..

“Effective February 21, 2023, the Company entered into a General Consulting and Services Agreement (the “Consulting Agreement”) with MCD Consulting and Management Services, LLC (“MCD”), the manager of which is Mr. Donegan, the Company’s Principal Financial Officer (“PFO”) and Principal Accounting Officer (“PAO”) and former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.”

Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance at TherapeuticsMD, Inc..

“terminated that certain amended and restated employment agreement, dated November 24, 2020, by and between the Company and Mr. Michael Donegan, the Company’s former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.”

Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance at TherapeuticsMD, Inc..

“Mr. Donegan is continuing to serve as the Company’s Principal Financial Officer and Principal Accounting Officer in a consulting capacity.”

TherapeuticsMD, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 6, 2023, TherapeuticsMD, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it was not in compliance with the rules for continued listing as set forth in Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”) due to the Company’s failure to hold an annual meeting of stockholders within 12 months after its fiscal year ended December 31, 2021. The Notice has no immediate effect on the listing of the Company’s common stock, par value $0.001 per share (“Common Sto”

Marlan Walker was appointed as Chief Executive Officer at TherapeuticsMD, Inc..

“On January 4, 2023, the Board appointed Mr. Marlan Walker, the Company’s General Counsel, as the Company’s Chief Executive Officer and Principal Executive Officer.”

Mark Glickman was terminated as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..

“On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.”

Brian Bernick was terminated as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..

“On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.”

TherapeuticsMD, Inc. completed a disposition involving Mayne Pharma LLC for $140.0 million cash at closing (closed 2022-12-30).

“consideration from Mayne Pharma to the Company for the purchase of the Transferred Assets and the grant of the licenses under the License Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition of net working capital as determined in accordance with the Transaction Agreement”

TherapeuticsMD, Inc. terminated Financing Agreement with Sixth Street Specialty Lending, Inc., as administrative agent.

“On the Closing Date, the Company repaid all obligations under its Financing Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto, and certain of the Company’s subsidiaries party thereto from time to time as guarantors (the “Financing Agreement”) and the Financing Agreement was terminated.”

TherapeuticsMD, Inc. amended Transaction Agreement Amendment with Mayne Pharma.

“Also on the Closing Date, the Company and Mayne Pharma entered into Amendment No. 1 to the Transaction Agreement (the “Transaction Agreement Amendment”), pursuant to which the parties agreed to amend the mechanics for calculating the final net working capital under the Transaction Agreement.”

TherapeuticsMD, Inc. amended License Agreement Amendment with Mayne Pharma valued at approximately $1.0 million.

“On the Closing Date, the Company and Mayne Pharma entered into Amendment No. 1 to the License Agreement (the “License Agreement Amendment”). Pursuant to the License Agreement Amendment, Mayne Pharma agreed to pay the Company approximately $1.0 million in prepaid royalties on the Closing Date.”

Angus C. Russell resigned as Director at TherapeuticsMD, Inc..

“On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.”

Jules A. Musing resigned as Director at TherapeuticsMD, Inc..

“On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.”

Karen L. Ling resigned as Director at TherapeuticsMD, Inc..

“On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.”

Paul M. Bisaro resigned as Director at TherapeuticsMD, Inc..

“On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.”

TherapeuticsMD, Inc. entered into Transaction Agreement with Mayne Pharma LLC valued at $140.0 million (effective 2022-12-04).

“Pursuant to a Transaction Agreement, dated December 4, 2022, between the Company and Mayne Pharma (the “Transaction Agreement”), the Company agreed to sell to Mayne Pharma, at closing, certain assets for Mayne Pharma to sell, market, distribute, manufacture, and otherwise commercialize the Products in the United States, including the Company’s exclusive license from the Population Council to commercialize Annovera ® (the “Transferred Assets”).”

TherapeuticsMD, Inc. entered into License Agreement with Mayne Pharma LLC (effective 2022-12-04).

“Pursuant to a License Agreement, dated December 4, 2022, between the Company and Mayne Pharma (the “License Agreement”), the Company agreed to grant Mayne Pharma, at closing, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories.”

TherapeuticsMD, Inc. amended Amendment No. 17 with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto (the “Lenders”) valued at amendment fee in the amount of $750,000 (effective 2022-11-30).

“On November 30, 2022 (the “Amendment Date”), TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into Amendment No. 17 (“Amendment No. 17”) to that certain Financing Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto (the “Lenders”), and certain of the Company’s subsidiaries party thereto from time to time as guarantors (the “Financing Agreement”).”

TherapeuticsMD, Inc. reported the third quarter ended September 30, 2022 results: revenue $20.9 million, net income $29.0 million, EPS $3.13 per basic and diluted share.

“Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year”

TherapeuticsMD, Inc. entered into Lender Subscription Agreement with the Lenders (effective 2022-10-28).

“on October 28, 2022 the Company issued warrants (the “Lender Warrants”), to the Lenders to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement by and among the Company and the Lenders (the “Lender Subscription Agreement”), and the maturity date of the Financing Agreement was extended to November 30, 2022.”

TherapeuticsMD, Inc. entered into Subscription Agreement with Rubric Capital Management LP valued at $7 million (effective 2022-10-28).

“On October 28, 2022, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company issued and sold, in a private placement offering (the “Offering”), 7,000 shares of the Company’s Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), for an aggregate offering price of $7 million.”

Tommy Thompson was appointed as Executive Chairman at TherapeuticsMD, Inc..

“the Board appointed The Honorable Tommy Thompson, who previously served as the Company’s Chairman of the Board, as the Executive Chairman of the Board.”

Mark Glickman was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..

“On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers”

Brian Bernick was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..

“On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers”

Hugh O'Dowd departed as Chief Executive Officer at TherapeuticsMD, Inc..

“Mr. O’Dowd’s separation as the Company’s Chief Executive Officer is a termination without “Good Cause,””

Justin Roberts was appointed as Director at TherapeuticsMD, Inc..

“On and effective as of August 23, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Justin Roberts as a director to fill a newly created vacancy on the Board as a result of the Board’s increase in the size of the Board by one director to a total of nine directors.”

Michael C. Donegan was appointed as Interim Chief Financial Officer at TherapeuticsMD, Inc..

“Mr. Michael C. Donegan, the Vice President – Finance and Chief Accounting Officer of the Company, will succeed Mr. D’Arecca as Interim Chief Financial Officer and Principal Financial and Accounting Officer as of the effective date of Mr. D’Arecca’s resignation.”

James C. D’Arecca resigned as Chief Financial Officer at TherapeuticsMD, Inc..

“On March 14, 2022, Mr. James C. D’Arecca, the Chief Financial Officer and Principal Financial Officer of the Company, notified the Company of his decision to resign from such positions, effective as of April 1, 2022.”

Robert G. Finizio resigned as Vice Chair at TherapeuticsMD, Inc..

“On February 17, 2022, Mr. Robert G. Finizio notified TherapeuticsMD, Inc., a Nevada corporation (the “Company”), of his decision to resign from the board of directors of the Company and as Vice Chair thereof, effective immediately.”

Robert G. Finizio was terminated as Chief Executive Officer at TherapeuticsMD, Inc..

“Mr. Finizio’s separation as the Company’s Chief Executive Officer is a termination without “Cause,” as defined in that certain employment agreement”

Hugh O'Dowd was appointed as director at TherapeuticsMD, Inc..

“on December 18, 2021, the Board appointed Mr. O'Dowd as a director.”